tetano
Editor, Senior Moderator
Evid Based Complement Alternat Med. 2014;2014:151235. doi: 10.1155/2014/151235. Epub 2014 Nov 25.
[h=1]Efficacy and safety of clearing heat and detoxifying injection in the treatment of influenza: a randomized, double-blinded, placebo-controlled trial.[/h] Liu Y[SUP]1[/SUP], Huang Y[SUP]1[/SUP], Wei B[SUP]1[/SUP], Liu X[SUP]2[/SUP], Zhang Y[SUP]3[/SUP], Huang X[SUP]4[/SUP], Tan Y[SUP]5[/SUP], Sun Z[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Objective. To evaluate the efficacy and safety of CHDI in the treatment of influenza infection. Method. A randomized double-blind, double dummy trial was conducted. Influenza patients with a positive influenza A rapid test diagnosis were randomized to receive CHDI or oseltamivir. Primary outcome was assessed by the median fever alleviation time and clearance time, and secondary outcome was total scores of influenza symptoms. Results. One hundred thirty-nine participants were screened and 34 had a RT-PCR laboratory confirmation of influenza virus infection. Fever alleviation time was 2.5 and 5 hours in CHDI and oseltamivir, respectively, and fever clearance time was 32.5 and 49 hours. The HR of fever alleviation and clearance time shows no significant difference between two groups. Total scores of influenza symptoms descended significantly in both groups after treatment and descended more in CHDI than oseltamivir on day 2. Similar to total symptoms severity score, fever severity score descend more significantly in CHDI than oseltamivir on day 2, and there were no differences on other symptoms. Conclusions. CHDI have a similar effect to oseltamivir in reducing the duration of influenza illness. CHDI was well tolerated, with no serious adverse events noted during the study period.
PMID: 25506380 [PubMed] PMCID: PMC4260441 Free PMC Article
[h=1]Efficacy and safety of clearing heat and detoxifying injection in the treatment of influenza: a randomized, double-blinded, placebo-controlled trial.[/h] Liu Y[SUP]1[/SUP], Huang Y[SUP]1[/SUP], Wei B[SUP]1[/SUP], Liu X[SUP]2[/SUP], Zhang Y[SUP]3[/SUP], Huang X[SUP]4[/SUP], Tan Y[SUP]5[/SUP], Sun Z[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Objective. To evaluate the efficacy and safety of CHDI in the treatment of influenza infection. Method. A randomized double-blind, double dummy trial was conducted. Influenza patients with a positive influenza A rapid test diagnosis were randomized to receive CHDI or oseltamivir. Primary outcome was assessed by the median fever alleviation time and clearance time, and secondary outcome was total scores of influenza symptoms. Results. One hundred thirty-nine participants were screened and 34 had a RT-PCR laboratory confirmation of influenza virus infection. Fever alleviation time was 2.5 and 5 hours in CHDI and oseltamivir, respectively, and fever clearance time was 32.5 and 49 hours. The HR of fever alleviation and clearance time shows no significant difference between two groups. Total scores of influenza symptoms descended significantly in both groups after treatment and descended more in CHDI than oseltamivir on day 2. Similar to total symptoms severity score, fever severity score descend more significantly in CHDI than oseltamivir on day 2, and there were no differences on other symptoms. Conclusions. CHDI have a similar effect to oseltamivir in reducing the duration of influenza illness. CHDI was well tolerated, with no serious adverse events noted during the study period.
PMID: 25506380 [PubMed] PMCID: PMC4260441 Free PMC Article